Osteoprotegerin enhances osteogenesis of human mesenchymal stem cells

Tissue Engineering - Part A

Volumn 19, Issue 19-20, 2013, Pages 2176-2187

  Palumbo, Sunmi ^a   Li, Wan Ju ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Madison   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; FLOWCHARTING; OSTEOBLASTS; PROTEINS; STEM CELLS; TISSUE ENGINEERING;

BONE TISSUE ENGINEERING; CLINICAL APPLICATION; CONDITIONED MEDIUM; HUMAN MESENCHYMAL STEM CELLS; MESENCHYMAL STEM CELL; OSTEOBLAST CULTURES; OSTEOGENIC CAPACITY; OSTEOGENIC SUPPLEMENTS;

CELL CULTURE;

CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCALCIN; OSTEOPROTEGERIN;

ARTICLE; BONE DEVELOPMENT; BONE TISSUE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CULTURE MEDIUM; GENE EXPRESSION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MICROARRAY; TISSUE ENGINEERING;

CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; OSTEOPROTEGERIN; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84883684506     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2012.0550     Document Type: Article

References (42)

1. Jorgensen, C., Gordeladze, J., and Noel, D. Tissue engineering through autologous mesenchymal stem cells. Curr Opin Biotechnol 15, 406, 2004.
2. Siddappa, R., Fernandes, H., Liu, J., van Blitterswijk, C., and de Boer, J. The response of human mesenchymal stem cells to osteogenic signals and its impact on bone tissue engineering. Curr Stem Cell Res Ther 2, 209, 2007.
3. Seong, J.M., Kim, B.C., Park, J.H., Kwon, I.K., Mantalaris, A., and Hwang, Y.S. Stem cells in bone tissue engineering. Biomed Mater 5, 062001, 2010.
4. Ye, C.P., Heng, B.C., Liu, H., Toh, W.S., and Cao, T. Culture media conditioned by heat-shocked osteoblasts enhances the osteogenesis of bone marrow-derived mesenchymal stromal cells. Cell Biochem Funct 25, 267, 2007.
5. Osugi, M., Katagiri, W., Yoshimi, R., Inukai, T., Hibi, H., and Ueda, M. Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects. Tissue Eng Part A 18, 1479, 2012.
6. Birmingham, E., Niebur, G.L., McHugh, P.E., Shaw, G., Barry, F.P., and McNamara, L.M. Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. Eur Cell Mater 23, 13, 2012.
7. Csaki, C., Matis, U., Mobasheri, A., and Shakibaei, M. Coculture of canine mesenchymal stem cells with primary bone-derived osteoblasts promotes osteogenic differentiation. Histochem Cell Biol 131, 251, 2009.
8. Wang, Y., Volloch, V., Pindrus, M.A., Blasioli, D.J., Chen, J., and Kaplan, D.L. Murine osteoblasts regulate mesenchymal stem cells via WNT and cadherin pathways: mechanism depends on cell-cell contact mode. J Tissue Eng Regen Med 1, 39, 2007.
9. Handorf, A.M., and Li, W.J. Fibroblast growth factor-2 primes human mesenchymal stem cells for enhanced chondrogenesis. PLoS One 6, e22887, 2011.
10. Inaba, M., Terada, M., Koyama, H., et al. Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 10, 1050, 1995.
11. Miclau, T., Edin, M.L., Lester, G.E., Lindsey, R.W., and Dahners, L.E. Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 16, 509, 1998.
12. Qiu, N., Zhou, H., and Xiao, Z. Downregulation of PKD1 by shRNA results in defective osteogenic differentiation via cAMP/PKA pathway in human MG-63 cells. J Cell Biochem 113, 967, 2011.
13. Wang, W., Zhang, X., Zheng, J., and Yang, J. High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem 338, 115, 2010.
14. Blaker, J.J., Gough, J.E., Maquet, V., Notingher, I., and Boccaccini, A.R. In vitro evaluation of novel bioactive composites based on Bioglass-filled polylactide foams for bone tissue engineering scaffolds. J Biomed Mater Res A 67, 1401, 2003.
15. Lu, H.H., El-Amin, S.F., Scott, K.D., and Laurencin, C.T. Three-dimensional, bioactive, biodegradable, polymerbioactive glass composite scaffolds with improved mechanical properties support collagen synthesis and mineralization of human osteoblast-like cells in vitro. J Biomed Mater Res A 64, 465, 2003.
16. Causa, F., Netti, P.A., Ambrosio, L., et al. Poly-epsiloncaprolactone/ hydroxyapatite composites for bone regeneration: in vitro characterization and human osteoblast response. J Biomed Mater Res A 76, 151, 2006.
17. Boyce, B.F., and Xing, L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9 Suppl 1, S1, 2007.
18. Hess, K., Ushmorov, A., Fiedler, J., Brenner, R.E., and Wirth, T. TNFalpha promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-kappaB signaling pathway. Bone 45, 367, 2009.
19. Cho, H.H., Shin, K.K., Kim, Y.J., et al. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J Cell Physiol 223, 168, 2010.
20. Podolin, P.L., Callahan, J.F., Bolognese, B.J., et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4- fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 312, 373, 2005.
21. Hofbauer, L.C., Dunstan, C.R., Spelsberg, T.C., Riggs, B.L., and Khosla, S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250, 776, 1998.
22. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., and Osdoby, P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276, 20659, 2001.
23. Oshita, K., Yamaoka, K., Udagawa, N., et al. Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. Arthritis Rheum 63, 1658, 2011.
24. Mizuno, A., Amizuka, N., Irie, K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247, 610, 1998.
25. Shalhoub, V., Faust, J., Boyle, W.J., et al. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. J Cell Biochem 72, 251, 1999.
26. Min, H., Morony, S., Sarosi, I., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192, 463, 2000.
27. Simonet, W.S., Lacey, D.L., Dunstan, C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309, 1997.
28. Sandra, F., Hendarmin, L., and Nakamura, S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosisinducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol 42, 415, 2006.
29. Pritzker, L.B., Scatena, M., and Giachelli, C.M. The role of osteoprotegerin and tumor necrosis factor-related apoptosisinducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15, 2834, 2004.
30. Shimizu, T., Ishikawa, T., Iwai, S., et al. Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma. Mol Cancer Res 10, 454, 2012.
31. Czekanska, E.M., Stoddart, M.J., Richards, R.G., and Hayes, J.S. In search of an osteoblast cell model for in vitro research. Eur Cell Mater 24, 1, 2012.
32. Jung, Y., Wang, J., Song, J., et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood 110, 82, 2007.
33. Giuliani, N., Pedrazzoni, M., Passeri, G., and Girasole, G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 27, 38, 1998.
34. Pautke, C., Schieker, M., Tischer, T., et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res 24, 3743, 2004.
35. Yao, Y., Wang, G., Wang, Z., Wang, C., Zhang, H., and Liu, C. Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs. J Oral Maxillofac Surg 69, e446, 2011.
36. Ito, T., Sawada, R., Fujiwara, Y., and Tsuchiya, T. FGF-2 increases osteogenic and chondrogenic differentiation potentials of human mesenchymal stem cells by inactivation of TGF-beta signaling. Cytotechnology 56, 1, 2008.
37. Quarto, N., and Longaker, M.T. FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state. Tissue Eng 12, 1405, 2006.
38. Tak, P.P., and Firestein, G.S. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107, 7, 2001.
39. Chang, J., Wang, Z., Tang, E., et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15, 682, 2009.
40. Baud'huin, M., Lamoureux, F., Duplomb, L., Redini, F., and Heymann, D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 64, 2334, 2007.
41. Schneeweis, L.A., Willard, D., and Milla, M.E. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280, 41155, 2005.
42. Hakeda, Y., Kobayashi, Y., Yamaguchi, K., et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 251, 796, 1998.